MedTrace Logo

MelaMEd Online Training for General Practitioners to Improve Melanoma Detection and Management

NCT07757386 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1531

Last updated 2026-08-11

No results posted yet for this study

Summary

The goal of this trial was to learn whether the MelaMEd online training program could improve doctors' skills in the early detection and management of melanoma, the most aggressive type of skin cancer. The participants were primary care physicians, including general practitioners, general practice trainees, and pediatricians.

The main questions were:

Did the training improve doctors' ability to identify skin lesions that might be melanoma? Did the training improve their knowledge of melanoma prevention, diagnosis, and management? Did the training help doctors make better decisions about referring patients to a dermatologist?

Participants first completed an online questionnaire. It included questions about melanoma and images of skin lesions. Participants then completed the MelaMEd online training course.

After the training, participants completed a second questionnaire with the same main questions. They also answered questions about their confidence in managing melanoma and their experience with the course.

Researchers compared each participant's answers before and after the training. There was no separate comparison group.

Conditions

Interventions

BEHAVIORAL

MelaMEd Online Training Program

The intervention was a free, self-paced asynchronous e-learning course titled "Early Diagnosis and Management of the Therapeutic Diagnostic Pathway of Melanoma," integrated with the MelaMEd multimedia platform. The course included video lectures and interactive clinical cases covering melanoma risk factors, sun exposure and photoprotection, skin examination, clinical recognition rules such as the ABCDE rule, the EFG rule, and the "Ugly Duckling" sign, histopathological diagnosis, surgical and medical treatment, staging, prognosis, and referral decision-making. The linked MelaMEd platform provided clinical, dermoscopic, and histological images, interactive educational resources, and access to guidelines and scientific literature.

Sponsors & Collaborators

  • Intergruppo Melanoma Italiano

    collaborator OTHER

  • Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

    lead OTHER

Principal Investigators

  • Ignazio Stanganelli, MD · Skin Cancer Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-06-01
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07757386 on ClinicalTrials.gov